Skip to main content
ModernaEarnings

Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction

Source: Autobound Signal API · 106 signals tracked for Moderna · updated

Get Moderna's live signals in Claude or ChatGPT, or by API

AskWhat changed at Moderna this week? Use Autobound signals for modernatx.com.

What happened

Moderna reported net income of $162 million for the third quarter.

Source

Article excerpt

In this article Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. "The new product and the diversification of geography is what has led to such a strong Q3," Moderna CEO Stéphane Bancel said in an interview ahead of the results. For example, he said the company is seeing the "full-year impact" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. Bancel noted that Covid is a seasonal business and vaccine contracts are typically established in the first quarter, so Moderna's shot only had a "small launch" to start with last year. Moderna's new stand-alone flu shot, which was approved in the U.S. in August, will similarly have a "limited launch" in the country in 2026 given the timing, he said. Here's what Moderna reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Moderna's third-quarter revenue jumped 29% to $1.31 billion, boosted by higher Covid vaccine sales in international markets and helped by deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million in international markets. The company posted a net income of...

Keep reading with a free account

The rest of this article, and every signal for Moderna, is in your free account.

Extracted from this sentence

The company posted a net income of $162 million, or 38 cents per share, for the third quarter.

Extracted by Autobound

From the Signal API record
Event
Earnings

What this signalsEarnings results often set the next budget cycle.

Amount named
$162M
Takes effect
Nov 6, 2026

The full record

From the Signal API record

Numbers

Amount named in the story
$162M

Extraction

Confidence
95%
Detected
Nov 6, 2026
signal_type
news
signal_subtype
has_earnings

Use this data

Get every earnings signal for Moderna and the companies you sell to, in the tools you already use.

  1. Ask Claude about it

    Connect Autobound to Claude, Claude Code or Cursor with MCP. Then ask: “What changed at Moderna this week?”

  2. Send it to your own tools

    The Signal API returns earnings signals for any list of companies as JSON, for your CRM, warehouse or app.

  3. Try it free

    Sign up and spend your free credits on the companies you sell to.

    Start Free1,000 free credits

The API returns more than this page shows

This page shows a preview. The full news record in the Signal API and MCP can also have these 8 fields. Some fields are empty for some signals.

Company

  • linkedin_urlValue in the API
  • industriesValue in the API
  • employee_count_lowValue in the API
  • employee_count_highValue in the API
  • revenueValue in the API
  • descriptionValue in the API

Signal

  • signal_nameValue in the API
  • associationValue in the API
Show the full JSONThe record on this page and the API request

GET /v1/signals/ecf43b9f-a4f0-b1dd-1d24-0f87d6543a15 returns this record as JSON. POST /v1/companies/enrich returns every signal for modernatx.com.

{
  "signal_id": "ecf43b9f-a4f0-b1dd-1d24-0f87d6543a15",
  "signal_type": "news",
  "signal_subtype": "has_earnings",
  "detected_at": "2026-11-06T11:47:42+00:00",
  "company": {
    "name": "Moderna",
    "domain": "modernatx.com"
  },
  "data": {
    "url": "https://www.cnbc.com/2026/11/06/moderna-mrna-earnings-q3-2026.html",
    "title": "Moderna raises 2026 outlook as CEO says newer vaccines are gaining traction",
    "excerpt": "In this article Moderna on Friday smashed third-quarter revenue and earnings estimates and hiked its outlook for full-year sales growth, as some of its newer products gain momentum. The biotech company now expects 2026 revenue growth of 15% to 25%, up from its previous guidance of up to 10%. \"The new product and the diversification of geography is what has led to such a strong Q3,\" Moderna CEO Stéphane Bancel said in an interview ahead of the results. For example, he said the company is seeing the \"full-year impact\" of its next-generation mRNA Covid vaccine, which won U.S. approval in May 2025. Bancel noted that Covid is a seasonal business and vaccine contracts are typically established in the first quarter, so Moderna's shot only had a \"small launch\" to start with last year. Moderna's new stand-alone flu shot, which was approved in the U.S. in August, will similarly have a \"limited launch\" in the country in 2026 given the timing, he said. Here's what Moderna reported for the third quarter compared with what Wall Street was expecting, based on a survey of analysts by LSEG: Moderna's third-quarter revenue jumped 29% to $1.31 billion, boosted by higher Covid vaccine sales in international markets and helped by deliveries under long-term government partnerships. Revenue was $780 million in the U.S. and $533 million in international markets. The company posted a net income of...",
    "summary": "Moderna reported net income of $162 million for the third quarter.",
    "planning": false,
    "image_url": "https://image.cnbcfm.com/api/v1/image/108222303-1762434766877-gettyimages-2235744008-CANADA_BIOMANUFACTURING.jpeg?v=1793926043&w=1920&h=1080",
    "confidence": 0.95,
    "published_at": "2026-11-06T11:47:42Z",
    "effective_date": "2026-11-06",
    "article_sentence": "The company posted a net income of $162 million, or 38 cents per share, for the third quarter.",
    "amount_normalized": 162000000
  }
}

Long text fields are shortened on this page.

Looking up one signal by its id is free. Enrich costs 2 credits per signal returned; a call with no results is free.